OncLive TV

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.

Luke Maese, DO, discusses treatment considerations for asparaginase-containing regimens in adult and young adult patients with ALL.

Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Cyrus M. Khan, MD, discusses how acalabrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Joseph Jacob, MD, MCR, discusses the potential role of an intravesical gemcitabine delivery system for BCG-unresponsive non–muscle-invasive bladder cancer.

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).